IGF-1 cohort study 2017 men
A cohort of 14 hypogonadal men on testosterone reported raised serum IGF-1 levels after growth hormone secretagogue therapy including sermorelin over 134 days. Reported in the cited paper.
SourceResearch Use Only. Products listed are not for human or animal consumption. Statements have not been evaluated by the FDA.View full disclaimers →

Sermorelin is a synthetic analogue of the first 29 amino acids of growth hormone releasing hormone. It was once approved as Geref for paediatric use but was withdrawn from the United States market in 2008, and now circulates mainly through compounding pharmacies.
Supplier listings
Form
Show prices as
Size
61 listings · Sermorelin
In stock5 mg · 3 vialsseen 1w ago
In stock10mgseen 7w ago
In stock2mgseen 5w ago
In stock5mgseen 7w ago
In stock5mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
In stock5mgseen 7w ago
In stock5mgseen 7w ago
In stock5mgseen 7w ago
In stock10mgseen 7w ago
In stock5mgseen 4w ago
In stock10mgseen 2w ago
In stock5mgseen 7w ago
In stock5mgseen 7w ago
In stock10mgseen 2w ago
In stock10mgseen 7w ago
In stock5mgseen 7w ago
In stock5mgseen 4w ago
In stock5mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
In stock5mgseen 7w ago
In stock10mgseen 7w ago
In stock13mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 6w ago
In stock10mgseen 7w ago
In stock5 mg · 2 vialsseen 3w ago
In stock5mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 2w ago
In stock10mgseen 7w ago
In stock5mgseen 7w ago
In stock5mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 7w ago
In stock10mgseen 4w ago
In stock2 mg · 10 vialsseen 7w ago
Out of stock10mgseen 7w ago
Overview
Sermorelin is a synthetic analogue of the first 29 amino acids of growth hormone releasing hormone. It was once approved as Geref for paediatric use but was withdrawn from the United States market in 2008, and now circulates mainly through compounding pharmacies.
What the research reports
Outcomes described across the published Sermorelin literature and ongoing study. Read each as research context rather than a promised personal result.
Physiological GH pulse release
Acts on the pituitary as a GHRH analogue, so release follows the body's own pulsatile pattern rather than overriding it. Reported in research settings.
IGF-1 elevation in cohorts
A 2017 cohort of 14 hypogonadal men on testosterone reported raised serum IGF-1 after growth hormone secretagogue therapy. Reported in research settings.
Circadian GH pulse context
Natural growth hormone release follows a pulsatile pattern concentrated overnight in humans. This physiological pattern is the basis for the drug class's mechanism, though no controlled trial on this page has measured outcomes tied to timing specifically.
Short acting release profile
The 10 to 20 minute half-life means exposure is brief, which is often presented as a safety argument for this class. Described in the research record.
Long clinical familiarity
The molecule has been in clinical use since the 1980s, giving prescribers a longer familiarity than most research peptides. Reported in research settings.
Clinical evidence
The published record for Sermorelin, labeled by strength so you can see what is settled and what is emerging.
A cohort of 14 hypogonadal men on testosterone reported raised serum IGF-1 levels after growth hormone secretagogue therapy including sermorelin over 134 days. Reported in the cited paper.
SourceA 2006 review argued sermorelin may be a better approach to adult onset growth hormone insufficiency than direct growth hormone replacement. Reported in the cited paper.
SourceA 2016 review of seizures across Europe found sermorelin among falsified biopharmaceutical injectables, a supply chain warning rather than efficacy data. Reported in the cited paper.
SourceInteractions
Questions